

TECHNOLOGY BRIEF

PROM

Clinician-reported Genetic testing Utility InDEx (C-GUIDE™)

Description

Decision makers require evidence of clinical utility to inform policy and funding decisions related to genetic testing. To address this, our inventors have developed and validated a novel outcome measure to assess the clinical utility of genetic testing from providers' perspectives.

The Clinician-reported Genetic testing Utility InDEx (C-GUIDE™) is designed to capture the clinical utility of a genetic test as it relates to:

- Understanding diagnosis and prognosis
- Informing medical management
- Awareness and actionability of reproductive and health risks for patients and family members
- Patient and family well-being

C-GUIDE™ is completed by clinicians that order, disclose, or manage genetic test results. It is available on paper or electronically and takes about 5 minutes to complete per patient

Therapeutic Area

- Genetic testing

Advantages

C-GUIDE is divided into three sections:

- Primary Findings: Genetic test results related to the primary indication for testing (includes 17 items).
- Secondary Findings: Genetic test results unrelated to the primary indication for testing but are still clinically relevant (includes 9 items).
- Pharmacogenomic Findings: Genetic test results related to genes that affect drug response (includes 4 items).

Additional Information

- Available in various languages.
- A version for use in prenatal care (C-GUIDE™ Prenatal) has been also validated and we are in the process of validating versions for critical care and newborn screening.
- We have also validated a patient-reported outcome measure called The Patient-reported Genetic testing Utility InDEx (P-GUIDE™) which is available for licensing.

Lead Inventor:

Robin Hayeems, ScM, PhD

Licensing Associate:

Karin Aguilar, karin.aguilar@sickkids.ca